Chemical Engineering researchers recognised for healthcare innovation at the RSC Biomaterials Chemistry Annual Conference
The University of Liverpool hosted this year’s conference, bringing together researchers from across the world all working together to advance biomaterial chemistry research and knowledge.
The conference highlighted the chemistries underlying the use of biomaterials in applications including antimicrobial surfaces, drug delivery and regenerative medicine. This year topics included anti-infective materials and device related infections, biomaterials for therapeutic delivery, biomaterials for tissue induction, regenerative medicine and bioresponsive surfaces.
Honey to fight antimicrobial resistance
Tom Hall, Doctoral Researcher in antimicrobial resistance solutions, won the 2019 Poster Prize for his work transforming delivery systems for Surgihoney RO™
to fight antimicrobial resistance. Tom works alongside Dr Sophie Cox
, Professor Liam Grover
and Matoke Holdings Ltd,
inventors of Reactive Oxygen® technology, who are developing innovative antimicrobial products
. Surgihoney RO™, an engineered honey, is the first ROS product invented by Matoke Holdings. It has been shown to be an effective treatment for infected and long-term or chronic wounds, such as leg ulcers, which can leave patients housebound, and in some cases lead to amputations.
Tom Hall, said:
“Antimicrobial resistance is such a massive problem. It is exciting to be involved in something that might be part of a solution. There is a need for this research, and I can see that my work has the potential to help people. That is the end goal. There can’t really be much of a bigger motivational force than helping to save peoples’ lives.”
Demineralising pathological bone
Tom Robinson, Doctoral Researcher in heterotopic ossification, won the 2019 Presentation Prize for his innovative work trying to demineralise pathological bone and improve the lives of combat injured personnel in collaboration with the Royal Centre for Defence Medicine (RCDM). Heterotopic ossification is a little known condition, but its effects can greatly impact the quality of life of sufferers. The aim of this project is to target the chemistry, rather than biology, in order to prevent and reverse ectopic bone formation.
Tom Robinson, said:
“The idea is that our approach can not only be used as an effective prevention, but also provide a key alternative to surgery to remove ectopic bone. Because of the way the treatment works, we’re hoping to extend its use to other pathological calcifications, such as kidney stones and band keratopathy in the eye. While we’re primarily focused on conditions affecting military personnel, our findings and any potential therapies can be extrapolated to the civilian population, hopefully, to provide new treatments to everyone suffering from these conditions.”